As GLP-1 receptor agonists (GLP-1s) like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) become increasingly common in the treatment of diabetes, obesity, and cardiovascular disease, retina specialists are paying close attention to whether the drug therapies may influence ocular disease in already high-risk patients
The reviewed studies have demonstrated that a variety of interventions can be effectively utilized to ameliorate typical ASD behavioral deficits
In response to nutrients, enteroendocrine L-cells and K-cells produce and release the incretin hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), respectively [2]
By binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, semaglutide produces several metabolic effects that fundamentally alter how patients experience eating and drinking
This product is supplied exclusively for research and development purposes.
DOI: 10.1016/j.eclinm.2026.103796 The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License